Skip to main content
logo
Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.23
-0.18 (-1.91%)
At close: Aug 20, 2026, 4:00 PM EDT
9.24
+0.01 (0.11%)
After-hours: Aug 20, 2026, 4:53 PM EDT

Xilio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
64.0943.776.34---
Revenue Growth
327.25%589.88%----
Gross Profit
53.343.776.34---
Selling, General & Admin
28.6329.7124.782729.9523.86
Research & Development
56.0456.0441.2152.1459.251.19
Operating Expenses
84.6785.7565.9979.1389.1575.04
Operating Income
-31.37-41.98-59.65-79.13-89.15-75.04
Interest Expense
----0.7-0.8-0.6
Other Non Operating Income (Expenses)
9.546.952.343.431.73-0.16
EBT Excluding Unusual Items
-21.83-35.04-57.3-76.4-88.22-75.8
Merger & Restructuring Charges
---0.94---
Pretax Income
-21.83-35.04-58.24-76.4-88.22-75.8
Net Income
-21.83-35.04-58.24-76.4-88.22-75.8
Net Income to Common
-21.83-35.04-58.24-76.4-88.22-75.8
Net Income Growth
------
Shares Outstanding (Basic)
754220
Shares Outstanding (Diluted)
754220
Shares Change
77.75%18.53%94.61%0.38%388.59%970.35%
EPS (Basic)
-3.32-7.73-15.24-38.90-45.09-189.29
EPS (Diluted)
-3.32-7.73-15.24-38.90-45.09-189.29
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-61.27-5.51-18.41-69.11-77.59-81.85
Free Cash Flow Per Share
-9.31-1.22-4.82-35.19-39.66-204.40
Gross Margin
83.16%100.00%100.00%---
Operating Margin
-48.94%-95.92%-940.18%---
Profit Margin
-34.06%-80.05%-918.05%---
Free Cash Flow Margin
-95.59%-12.59%-290.26%---
EBITDA
-30.03-40.44-58-77.23-87.3-73.55
EBITDA Margin
-46.85%-92.40%----
D&A For EBITDA
1.341.541.641.91.851.5
EBIT
-31.37-41.98-59.65-79.13-89.15-75.04
EBIT Margin
-48.94%-95.92%----
Revenue as Reported
64.0943.776.34---
SEC Filings: 10-K · 10-Q